

**** Materials for this course will release 05/16/2022 ****

Cardiology Self-Assessment Program (CardSAP) Book 1: Heart Failure (Cert # L229227)

Teaser: This Self-Assessment Program series provides Cardiology pharmacists with pertinent therapeutic updates to enhance their practice skills and improve patient outcomes.

Tag: Certifications; Cardiology



ACPE Numbers: Various – see listing below

Pre-Sale Date: 04/20/2022

Release Date: 05/16/2022

Expiration Dates: 11/15/2022

Activity Type: Application-based

CE Credits: TBD contact hours (BPS and ACPE)

Activity Fee: \$75 (ASHP member); \$110 (non-member)

Accreditation for Pharmacists



The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

Target Audience

The target audience for Cardiology Self-Assessment Program (CardSAP) Book 1: Heart Failure is board-certified cardiology pharmacy specialists caring for patients who have developed cardiac arrhythmias and/or thromboembolic disorders.

Activity Overview

This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). The course consists of 4 learning modules (see table below) and provides up to TBD contact hours of continuing pharmacy education and/or recertification credit.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ACCP and ASHP professional development program for BCCP recertification approved by the BPS.

Recertification Credit*

Board certified pharmacists are eligible to receive up to TBD contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

**** Materials for this course will release 05/16/2022 ****

Learning Activity	ACPE Number	Contact Hours	*Assessment Pass Point
Heart Failure I	0217-9999-22-040-H01-P	3.5	TBD
Heart Failure II	0217-9999-22-041-H01-P	4.5	TBD
Heart Failure III	0217-9999-22-042-H01-P	4.5	TBD
Heart Failure IV	0217-9999-22-043-H01-P	4.5	TBD

LEARNING OBJECTIVES

Heart Failure I

ACPE Number: 0217-9999-22-040-H01-P

Chapter: Universal Definition and Classification of Heart Failure

- Account for how heart failure (HF) is diagnosed using signs, symptoms, and other objective markers.
- Distinguish between existing definitions of HF related to ejection fraction and staging and the updated universal definition and classification of HF.
- Evaluate how changes to the definition of HF will affect future clinical research and therapeutic approaches.

Chapter: New Therapies for Chronic Heart Failure

- Analyze literature supporting the use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with chronic heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) for use in clinical decision-making.
- Evaluate literature assessing the use of SGLT2i in patients at risk of developing HFrEF including chronic kidney disease, diabetes, and/or atherosclerosis for use in clinical decision-making.
- Justify use of sacubitril/valsartan in patients with chronic heart failure with mildly reduced ejection fraction (HFmrEF) and/or chronic HFrEF with New York Heart Association (NYHA) functional class IV symptoms in the context of clinical decision-making.
- Assess literature supporting use of vericiguat in patients with chronic HFrEF for use in clinical decision-making.
- Develop an evidence-based pharmacotherapeutic regimen for a patient with chronic heart failure.

Heart Failure II

ACPE Number: 0217-9999-22-041-H01-P

Chapter: Optimal Management of Chronic Heart Failure During Hospitalization

- Design an evidence-based plan to optimize guideline-directed medical therapy and prevent the clinical sequelae of heart failure.
- Describe appropriate indications for holding guideline-directed medical therapy during acute decompensated heart failure and the impact on clinical outcomes after hospital discharge.
- Develop a follow-up plan to maintain and optimize pharmacologic therapy and prevent heart failure readmissions.

Chapter: Palliative Care for Patients with Heart Failure

- Assess the benefits of and barriers to palliative care or hospice referrals for patients with heart failure.
- Design evidence-based pharmacotherapy regimens for patients with common symptoms in heart failure including pain, dyspnea, and/or depression.
- Develop deprescribing recommendations for patients based on anticipated prognosis and agreed-upon goals of care.
- Apply pharmacologic and physiologic principles to end-of-life scenarios unique to the patients with heart failure.

**** Materials for this course will release 05/16/2022 ****

Heart Failure III

ACPE Number: 0217-9999-22-042-H01-P

Chapter: Cardiac Amyloidosis

- Distinguish the differences between light-chain (AL) amyloidosis and transthyretin-related amyloidosis (ATTR).
- Design an appropriate workup for a patient with cardiac amyloidosis.
- Develop an appropriate initial treatment regimen and monitoring plan for a patient with AL amyloidosis and ATTR on the basis of risk stratification.
- Develop appropriate counseling points on therapy recommendations for AL amyloidosis and ATTR.
- Apply best supportive care measures and monitoring for a patient with AL amyloidosis and ATTR.
- Assess the financial impact of therapy of disease-modifying agents in ATTR.

Chapter: Hypertrophic Cardiomyopathy

- Evaluate patients for patterns of inheritance for hypertrophic cardiomyopathy (HCM) and implications of genotypic carrier status and phenotypic expression of disease.
- Distinguish candidacy for HCM therapies based on presence of left ventricular outflow tract obstruction, persistence and severity of heart failure (HF) symptoms.
- Evaluate the place in therapy of pharmacotherapeutic treatments for symptomatic HCM including β -blockers, calcium channel blockers, disopyramide, and mavacamten.
- Justify recommendations for patients with HCM related to sudden cardiac death prevention, atrial fibrillation, exercise, and end-stage HF.

Heart Failure IV

ACPE Number: 0217-9999-22-043-H01-P

Interactive Case: Systematic Reviews and Meta-analysis in Heart Failure

- Differentiate systematic reviews and meta-analyses from other types of scientific reviews.
- Assess the credibility of systematic reviews and meta-analyses in heart failure (HF).
- Apply results from systematic reviews and meta-analyses in HF to clinical practice.

Interactive Case: Remote Patient Monitoring in Heart Failure

- Evaluate and monitor patients for heart failure (HF) signs and symptoms to reduce morbidity.
- Develop a noninvasive telemonitoring strategy to implement during a remote health visit.
- Justify the role of invasive monitoring devices and evaluate hemodynamic parameters.
- Assess a patient's HF medication regimen on the basis of subjective and objective evidence collected by modern telemonitoring modalities.
- Design a remote HF visit using tools for telemonitoring.

Disclosures

In accordance with our accreditor's Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

TBD

**** Materials for this course will release 05/16/2022 ****

All other persons in control of content do not have any relevant financial relationships with an ineligible company.

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

Development

These activities were developed by ACCP and ASHP.